SCHEMBL3907692

SCHEMBL3907692

COc1ccc(CC(OC(=O)N2CCOCC2)C(=O)NC(C)(C#N)OCc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTSS P25774 5/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FKBP1A P62942 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PSMB8 P28062 5/20 0.38
PSMB5 P28074 3/20 0.38
PSMB9 P28065 2/20 0.38
PSMB1 P20618 1/20 0.38
PSMB10 P40306 1/20 0.38
PSMB2 P49721 1/20 0.38
MMP8 P22894 1/20 0.38
YAP1 P46937 1/20 0.38
CTSL P07711 1/20 0.38
CTSK P43235 1/20 0.38
TACR2 P21452 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898080 0.94 MEN1 (0.46) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL3902172 0.92 CTSS (0.44) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL3892999 0.89 CTSS (0.42) CTSSMEN1KMT2ANPSR1ALDH1A1
SCHEMBL3906118 0.88 CTSS (0.43) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL3898098 0.86 CTSS (0.50) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL3897434 0.85 CTSS (0.48) CTSSMEN1KMT2ANPSR1ALDH1A1
SCHEMBL3896965 0.85 CTSS (0.47) CTSSMEN1KMT2ANPSR1FKBP1A
SCHEMBL3896883 0.85 CTSS (0.45) CTSSMEN1KMT2ANPSR1ALDH1A1
SCHEMBL3895845 0.85 MEN1 (0.43) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL3898209 0.85 CTSS (0.45) SMN1; SMN2CTSSMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP claimed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US claimed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US claimed
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP disclosed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US disclosed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases NOS1, CTSK, CTSS HPGD 1826/4885SMN1; SMN2 3560/4885CTSS 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.